

VOLUME 110 SUPPLEMENT 1995

Parasitology

Symposia of the British Society for Parasitology Volume 32

Parasite vaccines

EDITED BY **F. M. TOMLEY** and **D. W. TAYLOR**

CO-ORDINATING EDITOR **L. H. CHAPPELL**

CAMBRIDGE UNIVERSITY PRESS

Subscriptions may be sent to any bookseller or subscription agent or direct to the publisher: Cambridge University Press, The Edinburgh Building, Shaftesbury Road, Cambridge CB2 2RU. Subscriptions in the USA, Canada and Mexico should be sent to Cambridge University Press, Journals Department, 40 West 20th Street, New York, NY 10011-4211. All orders must be accompanied by payment. The subscription price (excluding VAT) of volumes 110 and 111, 1995 is £258 (US \$478 in the USA, Canada and Mexico), payable in advance, for ten parts plus supplements; separate parts cost £23 or US \$42 each (plus postage). EU subscribers (outside the UK) who are not registered for VAT should add VAT at their country's rate. VAT registered subscribers should provide their VAT registration number. Japanese prices for institutions (including ASP delivery) are available from Kinokuniya Company Ltd, P.O. Box 55, Chitose, Tokyo 156, Japan. Second class postage paid at New York, NY and at additional mailing offices. POSTMASTER: send address changes in USA, Canada and Mexico to *Parasitology*, Cambridge University Press, 110 Midland Avenue, Port Chester, New York, NY 10573-4930.

© Cambridge University Press 1995

The Pitt Building, Trumpington Street, Cambridge CB2 1RP
40 West 20th Street, New York, NY 10011-4211, USA
10 Stamford Road, Oakleigh, Melbourne 3166, Australia

Printed in Great Britain by the University Press, Cambridge

Parasitology

Symposia of the British Society for Parasitology Volume 32

Parasite vaccines

EDITED BY

F. M. TOMLEY AND D. W. TAYLOR

CO-ORDINATING EDITOR

L. H. CHAPPELL



CAMBRIDGE
UNIVERSITY PRESS

Contents

<i>Preface</i>	S1	Field trials of an asexual blood stage malaria vaccine: studies of the synthetic polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study	S25
<i>List of contributions</i>	S3	Summary	S25
Taenia ovis recombinant vaccine – ‘<i>quo vadit</i>’	S5	Introduction	S25
Summary	S5	Background to the U.S. sponsored phase IIb field trial of SPf66 in Thailand	S26
Introduction	S5	Epidemiologic assessment of the proposed study site	S27
The parasite	S5	Synopsis of the phase II protocol	S27
<i>T. ovis</i> recombinant vaccine	S5	Approaches to future studies	S28
Field trials with <i>T. ovis</i> recombinant antigen GST – 45 B/X	S6	Details of the analytic plan submitted to the U.S. FDA	S29
Further advances with recombinant <i>T. ovis</i> antigens	S7	Description of the study cohort by treatment assignment	S29
New cloned protective antigens	S7	Study cohorts and the safety subgroup	S30
Colostrum immunity	S8	Group assignment for children assigned incorrect vaccine	S30
Commercialization of the recombinant <i>T. ovis</i> vaccine	S8	Demographic variables: analysis	S30
Vaccination against other cestode species with recombinant antigens	S9	Analysis of baseline parameters	S31
A commercial vaccine for ovine toxoplasmosis	S11	Baseline studies for safety analysis	S31
Summary	S11	Follow-up of the study cohort	S31
Introduction	S11	Quality of data	S32
<i>Toxoplasma gondii</i>	S11	Analysis of safety data	S32
Ovine toxoplasmosis	S12	Primary efficacy analysis	S33
Immunity to <i>T. gondii</i>	S12	Secondary efficacy analysis	S33
A vaccine for sheep	S13	References	S35
Host response to the S48 vaccine	S14	Field trials of a recombinant rabies vaccine	S37
Conclusions	S14	Summary	S37
Acknowledgements	S14	Introduction	S37
References	S14	Control of fox rabies	S37
The development of oral vaccines against parasitic diseases utilizing live attenuated <i>Salmonella</i>	S17	Development of a vaccinia–rabies vector vaccine for oral vaccination of wildlife against rabies	S38
Summary	S17	Development of a vaccine–bait system	S39
Introduction	S17	Deliberate release of the vaccinia–rabies recombinant virus for oral vaccination of foxes against rabies	S39
Genetically defined attenuated <i>Salmonella</i> strains	S18	Towards elimination of rabies in Belgium?	S39
Evaluation of genetically defined strains in humans	S19	References	S41
The development of <i>Salmonella</i> as a carrier of heterologous antigens	S19	Commercialisation of a recombinant vaccine against <i>Boophilus microplus</i>	S43
Application of pTETnir15 to the development of an oral schistosomiasis vaccine	S20	Summary	S43
The development of vaccines against other parasitic infections	S21	Introduction	S43
Conclusions	S21	Development of a tick vaccine: stages in a long progression	S44
References	S21		

Stage 1: demonstration of feasibility	S44	Population dynamics and vaccine strategies	
Stage 2: efficacy in field trials	S45	for microparasites	S52
Stage 3: product registration	S46	Population dynamics and vaccine strategies	
Stage 4: the product in use	S48	for macroparasites	S53
Improvements in efficacy	S48	Cost and cost-effectiveness of vaccines	S55
The control of other tick species	S48	Conclusions	S57
Conclusions	S49	References	S57
References	S49		
The practicality and sustainability of			
 vaccination as an approach to			
 parasite control			
Summary	S51		
Introduction	S51		